CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
iOnctura is developing innovative cancer treatments, focusing on pancreatic cancer. Their lead drug, IOA-289, is a first-in-class inhibitor targeting the tumor-stroma-immune interface to combat cancer growth and resistance, aiming to improve patient outcomes in this challenging disease.
iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patents with unmet medical needs. iOnctura’s unique pipeline of drugs unlock mechanisms at the tumour-stroma-immune (T-S-I)
interface, a multi cell-network that is responsible for driving tumour growth and survival as well as treatment resistance.Pancreatic cancer is one of the most lethal cancers associated with devastating impact on the quality of life of
patients; current treatments…
IONCTURA BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
